Change of adviser and directorate update

RNS Number : 2815I
Venture Life Group PLC
23 November 2018

23 November 2018


Venture Life Group plc

("Venture Life" or "the Company")


Change of adviser and directorate update


Change of adviser

Venture Life Group plc (AIM: VLG), the international consumer self-care company, is pleased to announce the appointment, with immediate effect, of Cenkos Securities plc as its Nominated Adviser and sole broker.

Disclosures required by Schedule 2(g) of the AIM Rules for Companies

At the time of Venture Life's admission to trading on AIM on 24 March 2014, it was disclosed in the Company's admission document that Jerry Randall had been a director within the five years prior to date of publication of the admission document of Sinclair Pharma plc ("Sinclair Pharma") and Silence Therapeutics plc ("Silence Therapeutics") and various group companies of Sinclair Pharma and Silence Therapeutics. These group companies are Sinclair Pharma UK Limited, Sinclair Pharmaceuticals Limited, Silence Therapeutics (London) Limited and Innopeg Limited. Jerry Randall is also a director of Venture Life Limited and Lubatti Limited (both of which are Venture Life group companies) and was, until 8th March 2016, a director of Softto Lubatti Limited, a Venture Life group company.  Further, Sharon Collins is a director of Venture Life Limited and Lubatti Limited and a former director of Tracey Malone Originals Limited. Lastly, Gianluca Braguti is a director of Biokosmes SRL, a Venture Life group company.



Venture Life Group PLC

+44 (0) 1344 742870

Jerry Randall, Chief Executive Officer

Adrian Crockett, Chief Financial Officer  

Cenkos Securities PLC (Nominated adviser and sole broker)

+44 (0) 20 7397 8900

Mark Connelly / Cameron MacRitchie (Corporate Finance)

Michael F Johnson / Russell Kerr (Sales)

Walbrook PR

+ 44 (0) 20 7933 8780

Anna Dunphy /Paul McManus

+44 (0) 7876 741 001 / +44 (0) 7980 541 893




About Venture Life (

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product portfolio includes some key products such as the UltraDEX oral care products range, food supplements for lowering cholesterol and maintaining brain function, medical devices for women's intimate healthcare and haemorrhoids and dermo-cosmetics for addressing the signs of ageing.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.

Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit
UK 100

Latest directors dealings